老王v加速器2.2.16
Second Genome's proprietary Microbiome Discovery Platform uniquely addresses current limitations in target discovery and validation by:
- Integrating computational science and machine learning with human disease biology to redefine diseases
- 海外看中国_环球网 - huanqiu.com:2 天前 · “海外看中国”频道以海外媒体视角解读中国国内热点与焦点，帮助网友透过“第三只眼”看中国，了解世界媒体眼中的中国。主要有以下栏目：重 ...
- Generating libraries of compounds that are screened in traditional drug discovery and development assays
老王v加速器2.2.16
Our lead program, SG-2-0776, is a novel therapeutic protein derived from the microbiome that promotes mucosal healing of damaged epithelial surfaces. SG-2-0776 is currently in pre-clinical and IND-enabling studies, and we plan to initiate clinical development in 2021.
老王v加速器2.2.16
